George Lundberg, MD Editor in Chief at Cancer Commons

  • July 28, 2021  

    New Chronic Lymphocytic Leukemia Treatments 2021 Bookmark

    George Lundberg, MD

    TheSocialMedwork outlines several new drugs for treating chronic lymphocytic leukemia, including Brukinsa (zanubrutinib).

    .

  • July 28, 2021  

    Latest Advances in the Management of Classical Hodgkin Lymphoma: The Era of Novel Therapies Bookmark

    George Lundberg, MD

    This academic review paper from Blood Cancer Journal outlines many recent advances in the treatment of Hodgkin lymphoma, including for the 15-30% of patients who do not respond or relapse after conventional treatment.

    .

  • July 28, 2021  

    New Approvals for Liver Cancer Mark ‘Golden Age’ of Treatment Bookmark

    George Lundberg, MD

    Reported in Healio: After decades of little or no progress, many new clinical trials testing targeted and immunotherapy drugs—especially in combinations—are showing that they have real value in treating primary liver cancer (hepatocellular carcinoma).

    .

  • July 28, 2021  

    Oncolytic Virus Teserpaturev Approved in Japan for Malignant Glioma Bookmark

    George Lundberg, MD

    Oncolytic viruses may offer serious hope as a very new type of treatment for malignant glioma. As reported by OncLive, the oncolytic virus teserpaturev was recently approved in Japan after a phase 2 clinical trial.

    .

    .

  • July 28, 2021  

    2021 ASCO Annual Meeting Bookmark

    George Lundberg, MD

    Researchers at the 2021 annual meeting of the American Society of Clinical Oncology (ASCO) reported substantial advances in treatment for advanced esophageal, castration-resistant prostate, and metastatic nasopharyngeal cancers.

    .

  • July 28, 2021  

    ARIEL4 Trial Confirms PFS Benefit of Rucaparib in BRCA+ Relapsed Ovarian Cancer Bookmark

    George Lundberg, MD

    As reported by Cancer Network, new results from a phase 3 clinical trial testing the drug rucaparib (Rubraca), which has already been approved by the U.S. Food and Drug Administration, show that it prolongs progression-free survival in some patients with advanced ovarian cancer.

    .

  • July 28, 2021  

    FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy Bookmark

    George Lundberg, MD

    On May 28, 2021, the U.S. Food and Drug Administration granted Accelerated Approval for Lumakras (sotorasib), the first targeted therapy for cancer with a mutation in the KRAS gene.

    .

  • July 28, 2021  

    Advances in Colorectal Cancer Research Bookmark

    George Lundberg, MD

    This outline from the National Cancer Institute covers recent research on colorectal cancer.

    .

  • May 30, 2021  

    Cancer Support for LGBTQIA Patients Is Missing Bookmark

    George Lundberg, MD

    This piece from ASCO Connection outlines the need for and a path to improvement in cancer care for LGBTQIA patients.

    .

  • May 4, 2021  

    Hepatocellular Carcinoma (HCC)—An Overview Bookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    This 2020 encyclopedic approach to all of the many diagnostic and therapeutic options available for primary hepatocellular carcinoma leaves no stone unturned. (Free registration required, written with a physician audience in mind.)

    .